Ramos-Casals, Manuel
Brahmer, Julie R.
Callahan, Margaret K.
Flores-Chávez, Alejandra
Keegan, Niamh
Khamashta, Munther A.
Lambotte, Olivier
Mariette, Xavier
Prat, Aleix
Suárez-Almazor, Maria E.
Article History
Accepted: 2 March 2020
First Online: 7 May 2020
Competing interests
: M.R.-C. has received compensation for consulting services and/or speaking activities from Bristol-Myers Squibb and Gilead. J.R.B. has received compensation for consulting services and/or speaking activities from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech and Merck. M.K.C. declares institutional research support and employment of a family member by Bristol-Myers Squibb and consulting, advisory or speaking compensation from AstraZeneca/MedImmune, Incyte, Moderna and Merck. O.L. has received compensation for consulting services and/or speaking activities from AstraZeneca, Bristol-Myers Squibb France, Incyte, Janssen and MSD, and received research support from Gilead. X.M. has received compensation for consulting services and/or speaking activities from Bristol-Myers Squibb. A.P. has received compensation for consulting services and/or speaking activities from Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Oncolytics Biotech, Pfizer, Puma and Roche, and received research support from Boehringer Ingelheim, Nanostring, Novartis and Roche. M.E.S.-A. has received funding for consulting services from AbbVie, Agile Pharmaceuticals, Amag Pharmaceuticals, Eli Lilly and Pfizer unrelated to this topic. All other authors declare no competing interests.